The ketoconazole legacy

Clinical Pharmacology in Drug Development

Volumn 3, Issue 1, 2014, Pages 1-3

  Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A; KETOCONAZOLE;

DRUG ANTAGONISM; DRUG EXPOSURE; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; MYCOSIS; PRIORITY JOURNAL;

EID: 84892472719     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.100     Document Type: Editorial

References (37)

1. Petersen EA, Alling DW, Kirkpatrick CH. Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial. Ann Intern Med. 1980; 93:791-795.
2. Heiberg JK, Svejgaard E. Toxic hepatis during ketoconazole treatment. Br Med J (Clin Res Ed). 1981; 283:825-826.
3. Pegram PS, Kerns FT, Wasilauskas BL, Hampton KD, Scharyj M, Burke JG. Successful ketoconazole treatment of protothecosis with ketoconazole-associated hepatotoxicity. Arch Intern Med. 1983; 143:1802-1805.
4. van Tyle JH. Ketoconazole, Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984; 4:343-373.
5. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed). 1987; 294:419-422.
6. MacNair AL, Gascoigne E, Heap J, Schuermans V, Symoens J. Hepatitis and ketoconazole therapy. Br Med J. 1981; 283:1058.
7. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet. 1988; 14:13-1334.
8. Ferguson RM, Sutherland DE, Simmons RL, Najarian JS. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet. 1982; 2:882-883.
9. Daneshmend TK. Ketoconazole-cyclosporin interaction. Lancet. 1982; 2:1342-1343.
10. First MR, Schroeder TJ, Weiskittel P, Myre SA, Alexander JW, Pesce AJ. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet. 1989; 2:1198-1201.
11. Daneshmend TK, Warnock DW, Ene MD, et al. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. J Antimicrob Chemother. 1983; 12:185-188.
12. Blyden GT, Abernethy DR, Greenblatt DJ. Ketoconazole does not impair antipyrine clearance in humans. International Journal of Clinical Pharmacology. Ther Toxicol. 1986; 24:225-226.
13. Brown MW, Maldonado AL, Meredith CG, Speeg KV. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther. 1985; 37:290-297.
14. Heusner JJ, Dukes GE, Rollins DE, Tolman KG, Galinsky RE. Effect of chronically administered ketoconazole on the elimination of theophylline in man. Drug Intell Clin Pharm. 1987; 21:514-517.
15. Wahlländer A, Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol. 1989; 37:279-283.
16. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990; 264:2788-2790.
17. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA. 1993; 269:1513-1518.
18. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993; 269:1532-1536.
19. Watkins PB. Role of Cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis. 1990; 10:235-250.
20. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance. Clin Pharmacokinet. 2000; 38:111-180.
21. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol. 1994; 34:1222-1227.
22. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994; 56:601-607.
23. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther. 1996; 276:370-379.
24. Olkkola KT, Backman JT, Neuvinen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994; 55:481-485.
25. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic Cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999; 66:461-471.
26. Chen M, Nafziger AN, Bertino JS. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos. 2006; 34:2079-2082.
27. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998; 38:389-430.
28. Greenblatt DJ, von Moltke LL. Clinical Studies of Drug-Drug Interactions: Design and Interpretation. In: Pang KS, Rodrigues AD, Peter RM, editors. Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. New York: Springer; 2010. 625-649.
29. Greenblatt DJ, He P, von Moltke LL, Court MH. The CYP3 family. In: Ioannides C, editor. Cytochrome P450: Role in the Metabolism and Toxicology of Drugs and Other Xenobiotics. Cambridge (UK): Royal Society of Chemistry; 2008. 354-383.
30. von Moltke LL, Greenblatt DJ. Clinical drug interactions due to metabolic inhibition: Prediction, assessment, and interpretation. In: Lu C, Li AP, editors. Enzyme Inhibition in Drug Discovery and Development. Hoboken, NJ: John Wiley & Sons; 2010. 533-547.
31. Greenblatt DJ, Zhao Y, Venkatakrishnan K, et al. Mechanism of Cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol. 2011; 63:214-221.
32. Greenblatt DJ, Venkatakrishnan K, Harmatz JS, Parent SJ, von Moltke LL. Sources of variability in ketoconazole inhibition of human Cytochrome P450-3A in vitro. Xenobiotica. 2010; 40:713-720.
33. Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology. 1997; 25:103-107.
34. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999; 48:847-852.
35. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994; 330:263-272.
36. Song JC, Deresinski S. Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs. 2005; 6:170-177.
37. Yan JY, Nie XL, Tao QM, Zhan SY, Zhang YD. Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis. Biomed Environ Sci. 2013; 26:605-610.